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SUPPLEMENTARY NOTES
ABSTRACT
Mutations in mitochondrial DNA (mtDNA) are frequent in prostate cancer and they seem to occur early during prostate malignant transformation. Depletion of mtDNA in prostate cancer cells has been linked to acquisition of androgenindependence, progression to an invasive phenotype that is resistant to conventional chemotherapies, as well as induction of epithelial-mesenchymal transition leading to cancer metastasis. Using long-range genomic polymerase chain reaction, large deletion of mtDNA can be detected in prostate cancer tissues but not benign or normal prostate tissues. Noticeably, our study excludes the germ-line origin of the mutant mtDNA pattern in prostate cancer patient through analysis of the blood of the corresponding patient. Our data conclude that mtDNA deletion is due to carcinogenesis process in somatic prostate cells. In addition, our data have unveiled the molecular alteration in prostate cancer cells resulted from mtDNA deletion. For example, Skp2 protein elevation is often associated in prostate cells with loss of mtDNA. Also, the presence of Skp2 expression can decrease the expression of BRCA2 protein as an early biomarker of prostate neoplastic transformation, which is due to BRCA2 proteolysis.
SUBJECT TERMS
No subject terms provided. 
BODY
During the second year we have accomplished most of the planned experimental tasks. Part of the experiments planned for the second year has been already performed during the first year, as detailed below. An inverse correlation (Spearman's correlation coefficient: -0.67) was found between activity of mtDNA respiratory complexes, which was significantly decreased in prostate cancer, and the number of mtDNA deletions (Table 1) . We have analyzed BRCA2 mRNA levels and found no difference in mtDNA-mutated cells (Figure 1 ).
1.c Determine BRCA2 protein translation rate in wild-type and mutant mtDNA cells by incorporation of a radiolabeled aminoacidic precursor, followed by immunoprecipitation with anti-BRCA2 antibody and SDS-PAGE analysis (Months 14-16)
We measured BRCA2 protein translation and found a significant decrease in the rate of translation of BRCA2 in mtDNA-mutated cells (Figure 1) . We extended our analysis to other types of mtDNA-depleted/mutated cancer cells.
1.d Determine BRCA2 protein half-life in wild-type and mtDNA-mutated prostate cells by pulse-chase experiments. Eventually, identify proteolytic pathways involved in BRCA2 protein degradation, using specific inhibitors, and determine involvement of the ubiquitin ligase Skp2 in BRCA2 ubiquitination and degradation by Skp2 siRNA followed by quantification of total and ubiquitinated BRCA2 protein levels by immunoblotting (Months 17-19)
We determined BRCA2 protein half-life by incubating the cells with cycloheximide and measuring BRCA2 protein levels by Western blotting. We found a significant decrease in BRCA2 protein half-life in all mtDNA-mutated cells tested (Figure 2 ). We also analyzed the expression of Skp2, an E3 ubiquitin ligase involved in ubiquitination and proteasomal degradation of BRCA2 [2] , and of miR-1245, a miRNA recently shown to target BRCA2 3'-UTR and to inhibit its translation [3] . Skp2 protein and miR-1245 were increased in mtDNA-depleted cells (Figure 3 and data not shown). Inhibition of Skp2 expression by siRNA or use of a miR-1245 inhibitor alone partially recovered BRCA2 levels but their combination was able to completely restore BRCA2 to wild-type levels ( Figure 3) .
Task 2. Identify proteins differentially regulated by mutant mtDNA that may regulate loss of BRCA2 expression (Months 19-24)
2.a Identify proteins differentially regulated by mutant mtDNA using Clontech antibody microarrays and confirm results by immunoblotting (Months 19-21 We were able to generate C4-2 cells overexpressing BRCA2, but they show a mitotic arrest and it is impossible to perform experiments. Thus we have subcloned BRCA2 cDNA in a doxycycline-regulated system (pTet-OFF from Clontech) and generated stable clones overexpressing BRCA2 upon removal of doxycycline. We plan to start this task in the next months.
2.b Generate stable clones expressing luciferase (Months 22-23)
We tried to generate stable mtDNA-mutated clones overexpressing luciferase without success. We now think that it would be unlikely the generation of these clones because luciferase uses ATP for its activity, thus it depletes mtDNA-mutated cells of the energy required for anabolic processes and survival. Of note, mtDNA-mutated cells have reduced ATP levels due to dysfunctional oxidative phosphorylation.
KEY RESEARCH ACCOMPLISHMENTS
• Demonstration of correlation between loss of BRCA2 and number of mtDNA deletions in PCa.
• Demonstration of reduced translation and protein stability of BRCA2 in mtDNAmutated cells
• Demonstration of inverse correlation between loss of BRCA2 protein and increase in Skp2 levels and miR-1245 in mtDNA-mutated cells
REPORTABLE OUTCOMES
Publication
CONCLUSION
Our results provide evidence for a translational and post-translational mechanism of regulation of loss of BRCA2 protein following mtDNA mutations, that implicates both Skp2 and miR-1245 upregulation. In addition, we provide evidence for an inverse correlation between BRCA2 protein levels, the number of mtDNA deletions and Gleason grade in prostate carcinoma, suggesting that accumulation of mtDNA deletions may occur with progression of prostate cancer and further decrease BRCA2 levels in PCa. Tables 1-2 
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